Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial.

Publication ,  Journal Article
Campion, SL; Brenna, E; Thomson, E; Fischer, W; Ladell, K; McLaren, JE; Price, DA; Frahm, N; McElrath, JM; Cohen, KW; Maenza, JR; Walsh, SR ...
Published in: J Clin Invest
December 1, 2021

Naive and memory CD4+ T cells reactive with human immunodeficiency virus type 1 (HIV-1) are detectable in unexposed, unimmunized individuals. The contribution of preexisting CD4+ T cells to a primary immune response was investigated in 20 HIV-1-seronegative volunteers vaccinated with an HIV-1 envelope (Env) plasmid DNA prime and recombinant modified vaccinia virus Ankara (MVA) boost in the HVTN 106 vaccine trial (clinicaltrials.gov NCT02296541). Prevaccination naive or memory CD4+ T cell responses directed against peptide epitopes in Env were identified in 14 individuals. After priming with DNA, 40% (8/20) of the elicited responses matched epitopes detected in the corresponding preimmunization memory repertoires, and clonotypes were shared before and after vaccination in 2 representative volunteers. In contrast, there were no shared epitope specificities between the preimmunization memory compartment and responses detected after boosting with recombinant MVA expressing a heterologous Env. Preexisting memory CD4+ T cells therefore shape the early immune response to vaccination with a previously unencountered HIV-1 antigen.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

December 1, 2021

Volume

131

Issue

23

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Young Adult
  • Vaccinia virus
  • Vaccines, DNA
  • Middle Aged
  • Male
  • Immunology
  • Immunologic Memory
  • Immunization, Secondary
  • Immunity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Campion, S. L., Brenna, E., Thomson, E., Fischer, W., Ladell, K., McLaren, J. E., … McMichael, A. J. (2021). Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. J Clin Invest, 131(23). https://doi.org/10.1172/JCI150823
Campion, Suzanne L., Elena Brenna, Elaine Thomson, Will Fischer, Kristin Ladell, James E. McLaren, David A. Price, et al. “Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial.J Clin Invest 131, no. 23 (December 1, 2021). https://doi.org/10.1172/JCI150823.
Campion SL, Brenna E, Thomson E, Fischer W, Ladell K, McLaren JE, et al. Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. J Clin Invest. 2021 Dec 1;131(23).
Campion, Suzanne L., et al. “Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial.J Clin Invest, vol. 131, no. 23, Dec. 2021. Pubmed, doi:10.1172/JCI150823.
Campion SL, Brenna E, Thomson E, Fischer W, Ladell K, McLaren JE, Price DA, Frahm N, McElrath JM, Cohen KW, Maenza JR, Walsh SR, Baden LR, Haynes BF, Korber B, Borrow P, McMichael AJ. Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. J Clin Invest. 2021 Dec 1;131(23).

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

December 1, 2021

Volume

131

Issue

23

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Young Adult
  • Vaccinia virus
  • Vaccines, DNA
  • Middle Aged
  • Male
  • Immunology
  • Immunologic Memory
  • Immunization, Secondary
  • Immunity